Mentions
Extended reach
Total likes
Video views
AI synopsis
Discussions express strong agreement with the article, especially regarding the rapid action of biologics like ixekizumab and brodalumab, using words like 'most rapid response' and phrases such as 'transforming treatment.' Posts delve into specific details like week 2 outcomes and mention how these therapies improve patient satisfaction, reflecting high interest and acknowledgment of their importance in dermatology.
Most comments agree with the findings, highlighting the rapid effects of certain biologics like ixekizumab and brodalumab.
Discussions show high interest, with posts emphasizing treatment speed and benefits, signaling engagement with the topic.
Posts reference specific results, such as week 2 responses, indicating thoughtful engagement and deeper understanding.
The overall tone suggests acknowledgment of significant advancements in psoriasis treatment, implying high perceived impact.
Ixekizumab and brodalumab provide the most rapid response and earliest clinical benefit in Rx of Psoriasis at week 2 among the biologics. Have a renal TX pt with Psoriasis. No data in that group I guess @silvishah @raja_1980 @BhushanSree @SreejithDr https://t.co/FsvMx1e06L
RT @AdisJournals: Watch our latest video abstract accompanying a @DermatolTher meta-analysis! This short video is a great intro to the art…
RT @arvindcanchi: Ixekizumab and brodalumab provide the most rapid response and earliest clinical benefit in Rx of Psoriasis at week 2 amon…
Biologic therapies have transformed the treatment of moderate-to-severe #psoriasis and have markedly improved multiple #patient outcomes. This article: https://t.co/TYZhQldwYx investigates the rapid response of biologic treatments for moderate-to severe plaque #psoriasis https://t.co/GnSsS60Y0T
RT @arvindcanchi: Ixekizumab and brodalumab provide the most rapid response and earliest clinical benefit in Rx of Psoriasis at week 2 amon…
Watch our latest video abstract accompanying a @DermatolTher meta-analysis! This short video is a great intro to the article: https://t.co/yd6DxBEYrI #psoriasis #biologics #dermatology https://t.co/ro79Y53OkH
This study compares the speed of effectiveness of 11 biologic treatments for psoriasis over 12 weeks, highlighting brodalumab and ixekizumab as the fastest and most effective options for symptom improvement and quality…
RT @AdisJournals: Watch our latest video abstract accompanying a @DermatolTher meta-analysis! This short video is a great intro to the art…
Watch our latest video abstract accompanying a @DermatolTher meta-analysis! This short video is a great intro to the article: https://t.co/yd6DxBEYrI #psoriasis #biologics #dermatology https://t.co/ro79Y53OkH
RT @arvindcanchi: Ixekizumab and brodalumab provide the most rapid response and earliest clinical benefit in Rx of Psoriasis at week 2 amon…
RT @arvindcanchi: Ixekizumab and brodalumab provide the most rapid response and earliest clinical benefit in Rx of Psoriasis at week 2 amon…
Ixekizumab and brodalumab provide the most rapid response and earliest clinical benefit in Rx of Psoriasis at week 2 among the biologics. Have a renal TX pt with Psoriasis. No data in that group I guess @silvishah @raja_1980 @BhushanSree @SreejithDr https://t.co/FsvMx1e06L
RT @DermatolTher: Biologic therapies have transformed the treatment of moderate-to-severe #psoriasis and have markedly improved multiple #p…
Biologic therapies have transformed the treatment of moderate-to-severe #psoriasis and have markedly improved multiple #patient outcomes. This article: https://t.co/TYZhQldwYx investigates the rapid response of biologic treatments for moderate-to severe plaque #psoriasis https://t.co/GnSsS60Y0T
AC
KM
DT
AR
P